Baxdrostat/dapagliflozin

DRUG3 trials

Sponsors

AstraZeneca

Conditions

Chronic Kidney Disease and Hypertension

Phase 2

A Phase IIb Study to Evaluate the Effect of Dapagliflozin in Combination With Baxdrostat Compared With Baxdrostat on Albuminuria in Participants With Chronic Kidney Disease and High Blood Pressure.

Active, not recruitingNCT07222917

AstraZenecaChronic Kidney Disease and Hypertension

Start: 2025-12-05End: 2026-12-10Updated: 2026-09-01

Phase 3

A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.

Active, not recruitingNCT06268873

AstraZenecaChronic Kidney Disease and Hypertension

Start: 2024-03-29End: 2028-02-24Updated: 2026-06-26

A Phase III Renal Outcomes and Cardiovascular Mortality Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin in Participants With Chronic Kidney Disease and High Blood Pressure

RecruitingNCT06742723

AstraZenecaChronic Kidney Disease and Hypertension

Start: 2025-03-03End: 2029-12-18Target: 5000Updated: 2026-08-26

Related Papers

SGLT2 inhibitor with and without ALDosterone AntagonIst for heart failure with preserved ejection fraction: Design paper

ESC Heart Failure2025-05-193 citations

The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design

JAMA Network Open2024-12-1110 citations

The potential for improving cardio-renal outcomes in chronic kidney disease with the aldosterone synthase inhibitor vicadrostat (BI 690517): a rationale for the EASi-KIDNEY trial

Nephrology Dialysis Transplantation2024-11-1232 citations